TELA Bio, Inc. (TELA) - 10-K Filing Summary
Business Context and Reporting Period
Company: TELA Bio, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions. Its primary product portfolios are OviTex (hernia repair and abdominal wall reconstruction) and OviTex PRS (plastic and reconstructive surgery). The company relies on an exclusive manufacturing and supply agreement with Aroa Biosurgery Ltd. in New Zealand.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $80.3 million | $69.3 million | +16% |
| Gross Profit | $54.3 million | $46.5 million | +17% |
| Gross Margin | 68% | 67% | +100 bps |
| Net Loss | $(38.8) million | $(37.8) million | +3% (wider loss) |
| Operating Expenses | $88.1 million | $88.2 million | Flat |
| Cash and Equivalents | $50.8 million | $52.7 million | -4% |
| Working Capital | $57.6 million | $62.5 million | -8% |
| Long-Term Debt | $55.7 million (net) | $41.1 million (net) | Increased |
Note: 2024 results included a one-time gain of $7.6 million from the sale of the NIVIS product line to MiMedx Group, Inc.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 22% increase in OviTex unit sales (22,063 units vs. 18,121) and a 12% increase in OviTex PRS unit sales. Growth was partially offset by a decrease in average selling prices due to product mix shifts toward smaller units.
- Debt Restructuring: In November 2025, the company entered a new $70.0 million credit facility with Perceptive Credit Holdings V, LP. An initial $60.0 million loan was funded to repay the previous MidCap facility, resulting in a $0.9 million loss on extinguishment of debt.
- Equity Financing: In November 2025, the company completed a registered direct offering of 4.2 million shares and pre-funded warrants, raising approximately $11.6 million in net proceeds.
- Operating Expenses: Sales and marketing expenses decreased by 2% due to lower severance and travel costs, offsetting higher commissions. General and administrative expenses increased by 7% due to higher compensation and professional fees.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes existing cash resources ($50.8 million) and the new credit facility are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring operating losses as it invests in sales, marketing, and R&D.
Key Risks and Contingencies:
- Nasdaq Listing Compliance: On March 17, 2026, the company received a deficiency letter from Nasdaq because its closing bid price had been below $1.00 for 30 consecutive days. The company has 180 days (until September 14, 2026) to regain compliance or face delisting.
- Supply Chain Concentration: The company is 100% dependent on Aroa Biosurgery Ltd. in New Zealand for manufacturing. Any disruption at this single facility could halt production.
- Regulatory and Clinical: The company is pursuing FDA approval for OviTex PRS in breast reconstruction (requires PMA). Delays or failures in clinical trials or regulatory approvals could hinder growth.
- Macroeconomic Factors: Exposure to tariffs (10% on imports from New Zealand), inflation, and potential reductions in elective surgical volumes due to hospital financial strain or cybersecurity events.
Investor Verification Checklist
- Stock Price Compliance: Verify the company's progress in regaining Nasdaq compliance (minimum $1.00 bid price) before the September 2026 deadline.
- Debt Covenants: Review the specific revenue and liquidity covenants in the new Perceptive Credit Agreement to ensure the company remains in compliance.
- Manufacturing Capacity: Assess Aroa's ability to meet growing demand, given the single-source manufacturing risk and recent capacity expansions.
- Product Mix Impact: Monitor the trend in average selling prices (ASP) as the company shifts toward smaller unit sizes, which may pressure gross margins despite volume growth.
- Cash Burn Rate: Evaluate the sustainability of the current cash burn rate (~$28 million in operating cash outflow for 2025) against the $50.8 million cash balance and debt service requirements.